ERBB2 and breast cancer: found no correlation between FcγRIIa-131H/R and FcγRIIIa-158V/F SNPs and clinical outcome in a large retrospective cohort of over 1000 early HER2+ BC patients treated with adyuvant trastuzumab (105, 106).